Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB-Reference-Cited by-同舟云学术

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB

Published:2017-02-08 Issue:5 Volume:72 Page:1441-1449
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Naidoo Anushka¹,Chirehwa Maxwell²,McIlleron Helen²,Naidoo Kogieleum¹³,Essack Sabiha⁴,Yende-Zuma Nonhlanhla¹,Kimba-Phongi Eddy²,Adamson John⁵,Govender Katya⁵,Padayatchi Nesri¹³,Denti Paolo²

Affiliation:

1. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa

2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa

3. MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal

4. Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, South Africa

5. KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa

Funder

NIH

Fogarty International Center

Office of Global AIDS Coordinator and the U. S. Department of Health and Human Services, National Institutes of Health (NIH OAR and NIH OWAR)

the European & Developing Countries Clinical Trials Partnership (EDCTP)

National Research Foundation of South Africa

Columbia University-South Africa Fogarty AIDS260 International Training and Research Program

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/72/5/1441/24332194/dkx004.pdf

Reference53 articles.

1. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials;Moodley;Eur Respir Rev,2016

2. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis;Dawson;Lancet,2015

3. Moxifloxacin: an alternative to ethambutol for the treatment of presumed ocular tuberculosis;Potter;Ocul Immunol Inflamm,2015

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-12

2. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis;PLOS ONE;2024-09-06

3. Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing;Clinical Microbiology Reviews;2024-06-13

4. Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial;Trials;2024-05-08

5. Continuous evaluation of single-dose moxifloxacin concentrations in brain extracellular fluid, cerebrospinal fluid, and plasma: a novel porcine model;Journal of Antimicrobial Chemotherapy;2024-04-04